Ro67-4853: Difference between revisions

{{drugbox

| verifiedrevid = 392496469

| IUPAC_name = butyl (9H-xanthene-9-carbonyl)carbamate

| image = Ro67-4853_structure.png

| width = 200

| CAS_number =

| ATC_prefix =

| ATC_suffix =

| PubChem = 9949202

| DrugBank =

| C=19|H=19|N=1|O=4

| molecular_weight = 325.358 g/mol

| smiles = c3cccc2c3Oc1ccccc1C2C(=O)NC(=O)OCCCC

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->

| pregnancy_US = <!-- A / B / C / D / X -->

| pregnancy_category=

| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->

| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->

| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->

| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->

| legal_status =

| routes_of_administration =

'''Ro67-4853''' is a drug used in scientific research, which acts as a selective [[Allosteric modulation|positive allosteric modulator]] for the [[metabotropic glutamate receptor]] subtype [[Metabotropic glutamate receptor 1|mGluR₁]].<ref name="pmid11606768">{{cite journal |author=Knoflach F, Mutel V, Jolidon S, Kew JN, Malherbe P, Vieira E, Wichmann J, Kemp JA |title=Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site |journal=Proceedings of the National Academy of Sciences of the United States of America |volume=98 |issue=23 |pages=13402–7 |year=2001 |month=November |pmid=11606768 |pmc=60883 |doi=10.1073/pnas.231358298 |url=}}</ref><ref name="pmid16645124">{{cite journal |author=Hemstapat K, de Paulis T, Chen Y, Brady AE, Grover VK, Alagille D, Tamagnan GD, Conn PJ |title=A novel class of positive allosteric modulators of metabotropic glutamate receptor subtype 1 interact with a site distinct from that of negative allosteric modulators |journal=Molecular Pharmacology |volume=70 |issue=2 |pages=616–26 |year=2006 |month=August |pmid=16645124 |doi=10.1124/mol.105.021857 |url=}}</ref><ref name="pmid18625258">{{cite journal |author=Sheffler DJ, Conn PJ |title=Allosteric potentiators of metabotropic glutamate receptor subtype 1a differentially modulate independent signaling pathways in baby hamster kidney cells |journal=Neuropharmacology |volume=55 |issue=4 |pages=419–27 |year=2008 |month=September |pmid=18625258 |doi=10.1016/j.neuropharm.2008.06.047 |url= |pmc=2600811}}</ref> It was derived by modification of the simpler compound [[Ro01-6128]], and has itself subsequently been used as a [[lead compound]] to develop a range of potent and selective mGluR₁ positive modulators.<ref name="pmid16099654">{{cite journal |author=Vieira E, Huwyler J, Jolidon S, Knoflach F, Mutel V, Wichmann J |title=9H-Xanthene-9-carboxylic acid [1,2,4]oxadiazol-3-yl- and (2H-tetrazol-5-yl)-amides as potent, orally available mGlu1 receptor enhancers |journal=Bioorganic & Medicinal Chemistry Letters |volume=15 |issue=20 |pages=4628–31 |year=2005 |month=October |pmid=16099654 |doi=10.1016/j.bmcl.2005.05.135 |url=}}</ref><ref name="pmid19233648">{{cite journal |author=Vieira E, Huwyler J, Jolidon S, Knoflach F, Mutel V, Wichmann J |title=Fluorinated 9H-xanthene-9-carboxylic acid oxazol-2-yl-amides as potent, orally available mGlu1 receptor enhancers |journal=Bioorganic & Medicinal Chemistry Letters |volume=19 |issue=6 |pages=1666–9 |year=2009 |month=March |pmid=19233648 |doi=10.1016/j.bmcl.2009.01.108 |url=}}</ref>

== References ==

{{Reflist}}

{{Glutamate_receptor_ligands}}

{{pharm-stub}}

[[Category:Hoffmann-La Roche]]

[[Category:xanthenes]]